NCT03813836

Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC

A Phase II Trial to Assess the Efficacy and Safety Profile of Pembrolizumab in Patients With Performance Status 2 With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: University College, London · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A single-arm phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status of 2 with recurrent or metastatic squamous cell carcinoma of the head and neck. Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months

Conditions

• Metastatic Head and Neck Squamous Cell Carcinoma
• Recurrent Head and Neck Squamous Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months

Timeline

• Start date: 2019-07-05
• Primary completion: 2024-01-10
• Completion: 2026-01-31
• First posted: 2019-01-23
• Last updated: 2024-11-12

Locations

12 sites across 1 country: United Kingdom